Clinical Trial

MicroRNA as Markers in Testicular Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of this study is establish the performance of miR371 in management of testicular cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-06-03.
Trial Details
NCT Number NCT04914026
Lead Sponsor Haukeland University Hospital
Collaborators: Karolinska University Hospital, Sahlgrenska University Hospital, Helse Fonna, University Hospital of North Norway, Oslo University Hospital
Conditions Testicular Germ Cell Cancer, Seminoma, Non-Seminoma Testicular Cancer, Stage I Testicular Cancer, Stage II Testicular Cancer, Stage III Testicular Cancer, Stage IV Testicular Cancer, Relapse Testicular Cancer
Enrollment 350 participants
Start Date 2016-12-31
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-08-08